Rx Product News (June 2018)
Read about the Rx products featured in June.
INDICATION: The FDA has expanded the indication of Allergan’s ceftazidime and avibactam (Avycaz), approving the antibiotic to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
DOSAGE FORM: Single-use vial for intravenous infusion: 2.5 g
FOR MORE INFORMATION: allergan.com
HIZENTRAMANUFACTURED BY: CSL Behring
INDICATION: The FDA has expanded the indication of CSL Behring’s immune globulin subcutaneous (Human) 20% liquid (Hizentra), approving the drug to prevent relapse of neuromuscular disability and impairment in patients with chronic inflammatory demyelinating polyneuropathy.
DOSAGE FORM: Solution for subcutaneous injection: 0.2 g/ml
FOR MORE INFORMATION: cslbehring.com
ILUMYAMANUFACTURED BY: Sun Pharmaceutical Industries Ltd
INDICATION: The FDA has approved Sun Pharma’s tildrakizumab-asmn (Ilumya) to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DOSAGE FORM: Solution for subcutaneous injection: 100 mg/ml
FOR MORE INFORMATION: sunpharma.com
TASIGNAMANUFACTURED BY: Novartis
INDICATION: The FDA has expanded the indication of Novartis’ nilotinib (Tasigna), approving the kinase inhibitor to treat pediatric patients 1 and older who are undergoing firstor second—line pediatric treatment for Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
DOSAGE FORM: Capsules: 50,150, and 200 mg FOR
MORE INFORMATION: novartis.com